Intervacc signs agreement for optimization of manufacturing

Intervacc is pleased to announce that an agreement has now been signed with PX´Therapeutics, Grenoble, France, for process optimization of Strangvac. PX´Therapeutics, a subsidiary of Aguettant pharmaceutical group, has the experience, facilities and personnel to produce recombinant proteins from E. coli in compliance with GMP.

The aim is to obtain a more efficient and cost effective production of Strangvac®, which is composed of three recombinant proteins. Initial work on optimization has already begun and Intervacc foresees a smooth transfer of production technology and analytical procedures associated with the manufacturing process.

Date Created
2015-10-28